Med-X, a manufacturer of natural pesticides and other environmentally focused products, has filed with the U.S. Securities and Exchange Commission to register its shares for a direct listing on the Nasdaq. Unlike a traditional IPO, the company will not raise new capital from the listing, with existing shareholders instead registering up to 13.1 million shares for potential sale.

Company Background

Med-X develops and markets natural products through its Nature-Cide, Thermal-Aid and Malibu Brands divisions. The company focuses on products positioned as natural or “green” alternatives across pest control, agriculture, hospitality and consumer health applications.

Its Nature-Cide division produces minimum-risk botanical pesticides and repellents for professional pest control, hospitality, agriculture and other applications. Thermal-Aid develops natural heating and cooling products designed for pain relief.

Both product lines are distributed through national distributors and ecommerce platforms. During the six months ended June 2025, Nature-Cide represented approximately 54% of company revenue, while Thermal-Aid accounted for approximately 44%.

Med-X is based in Canoga Park, California, and was founded in 2014. The company generated approximately $2 million in revenue for the 12 months ended June 30, 2026.

Direct Listing Details

Med-X has registered up to 13.1 million shares of common stock, representing all of the company’s outstanding shares. The registered shares will be sold by existing shareholders, meaning Med-X itself will not receive proceeds from the transactions.

The company plans to list on the Nasdaq under the symbol MXRX. Because the transaction is structured as a direct listing without a firm-commitment offering, there are no traditional IPO underwriters.

Maxim Group will instead serve as Med-X’s financial advisor.

Med-X previously pursued a conventional IPO, initially filing in September 2022. The company amended the proposed offering terms several times before withdrawing its registration statements in April 2024. Its most recent proposed IPO had contemplated a market capitalization of approximately $26 million.

Business Model & Market Position

Med-X’s business combines natural pest-control products with consumer-oriented heating and cooling products. Nature-Cide provides exposure to professional and commercial applications, while Thermal-Aid serves consumer health and pain-relief markets.

The company’s use of national distributors and ecommerce platforms gives its products multiple distribution channels. The revenue contribution from Nature-Cide and Thermal-Aid also indicates that these two divisions represent the primary components of Med-X’s current business.

The direct listing structure provides existing shareholders with a mechanism to sell registered shares on the public market without the company conducting a new capital raise.

Risks & Challenges

Med-X enters the public market with relatively modest revenue, having generated approximately $2 million during the 12 months ended June 30, 2026. Its business is also concentrated primarily in Nature-Cide and Thermal-Aid, which accounted for approximately 98% of revenue combined during the six months ended June 2025.

Unlike a traditional IPO, Med-X will not receive new capital from the direct listing. This means the transaction itself will not provide the company with additional proceeds to fund expansion, product development or other corporate initiatives.

The company’s previous attempts to pursue a conventional IPO also demonstrate that its path to the public markets has undergone multiple changes since the initial 2022 filing.

Market Context & Opportunities

The direct listing gives Med-X access to the public equity markets while allowing existing shareholders to register their holdings for potential sale. The company’s product portfolio is centered on natural pesticides, repellents and pain-relief products, with sales occurring through both distributors and ecommerce channels.

Future growth will depend on the company’s ability to expand its product lines and distribution while increasing revenue across its existing brands. However, the supplied filing information does not provide specific financial projections or a valuation for the direct listing.

Closing Paragraph

Med-X is preparing to enter the Nasdaq through a direct listing that will register up to 13.1 million shares held by existing shareholders. With approximately $2 million in trailing revenue and no new capital being raised through the transaction, the listing represents a different route to the public markets from the traditional IPO structure the company previously pursued.